PHARMANIAGA BHD
KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.44
Today's Change
-0.005 (1.12%)
Day's Change
0.44 - 0.445
Trading Volume
50,900
Financial
T4Q
31-Mar-2021
2020
31-Mar-2021
2019
31-Mar-2021
2018
31-Mar-2021
2017
31-Mar-2021
Total assets
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current assets
238
1000
110
900
600
Cash & equivalents
238
1000
110
900
600
Short term investments
238
1000
110
900
600
Total receivables, net
238
1000
110
900
600
Accounts receivable - trade, net
238
1000
110
900
600
Other receivables
238
1000
110
900
600
Total inventory
238
1000
110
900
600
Inventories - work in progress
238
1000
110
900
600
Inventories - progress payments & other
238
1000
110
900
600
Inventories - finished goods
238
1000
110
900
600
Inventories - raw materials
238
1000
110
900
600
Total non-current assets
238
1000
110
900
600
Long term investments
238
1000
110
900
600
Note receivable - long term
238
1000
110
900
600
Investments in unconsolidated subsidiaries
238
1000
110
900
600
Other investments
238
1000
110
900
600
Net property/plant/equipment
238
1000
110
900
600
Gross property/plant/equipment
238
1000
110
900
600
Accumulated depreciation, total
238
1000
110
900
600
Deferred tax assets
238
1000
110
900
600
Net intangible assets
238
1000
110
900
600
Other current assets, total
238
1000
110
900
600
Total liabilities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current liabilities
-238
-1000
-110
-900
-600
Total non-current liabilities
-238
-1000
-110
-900
-600
Long term debt
238
1000
110
900
600
Long term debt excl. lease liabilities
238
1000
110
900
600
Capital and operating lease obligations
238
1000
110
900
600
Provision for risks & charge
-238
-1000
-110
-900
-600
Deferred tax liabilities
-238
-1000
-110
-900
-600
Other liabilities, total
-238
-1000
-110
-900
-600
Total equity
-238
-1.64%
-1000
+11.55%
-110
+81.66%
-900
-13.16%
-600
+235.36%
Total liabilities & shareholders' equities
238B
1000B
110B
900B
600B
Total debt
238
1000
110
900
600
Book value per share
-238
-1000
-110
-900
-600
Discussions
6 people like this. Showing 50 of 14,035 comments
Kumpul dana lagi. ha
https://www.nst.com.my/business/2023/07/933425/pharmaniaga-completes-share-placement-exercises
2 months ago
2nd PP to raise pocket change of 50 mill for working Capital???.........out of cash in Hand???
So, how to settle the 1 Billion Debts looming large??????? Mind you, it's 1 Billion, not 10 mill or 50 mill........!!
2 months ago
PP again for 50 mill....piggy bank smashed, Milo tin already kosong....RED Flags...........
Price should be at 12c........and below 10c upon legal actions from Banks.
2 months ago
look this: https://www.businesstoday.com.my/2023/07/06/affin-banks-credit-costs-and-nim-issues-to-persists-midf/
Affin will have higher bad debt next quarter concurrent with expire of vaccine. Since under same group, boleh bincang la...😁
2 months ago
Pelan utk keluar dr PN 17
https://www.nst.com.my/business/2023/07/935341/pharmaniaga-sees-clear-plan-end-year
2 months ago
wow booster vaccine Viagra come again ... high target price will achieve soon ...
2 months ago
BobAssshole bodoh the Pharma share price already almost up 100% from bottom.
This kind of bodoh bookworm how to make money in share market? Adui!
2 months ago
Bursa Red light 2nd PP........hitting brickwall now.....
https://www.msn.com/en-my/money/topstories/bursa-securities-unable-to-consider-pharmaniaga-s-second-private-placement/ar-AA1ermKF?ocid=hpmsn&cvid=7cf6d4d36d30411f8985e04e4294ba90&ei=14
2 months ago
SC is doing the right job to ban 2nd PP. This GLC is making the bad example to ruin Bursa regulation. If 2nd, 3rd PP and plus can be done in the same year, what is the meaning of requiring Shareholders approval for 10% issuing limit?
1 month ago
told you guys.. fake push to trap people.. regularisation not yet even submitted.
3 weeks ago
Your name is deceiving- how to trust? Why don't u upgrade it to Old/Experiencedplayer ?
2 weeks ago
Exactly....................(for window dressing only during this season of red sea)
2 weeks ago
If compare with other Sifu I’m still a potato ma. Let’s see it together. I also curious how high this stock can fly.
2 weeks ago
On the sector outlook, Kenanga noted global healthcare expenditures are projected to reach a total of US$10 trillion by 2026, increasing from US$8.4 trillion in 2022. — Bloomberg
PETALING JAYA: In the recently-concluded second quarter 2023 (2Q23) results, companies in the healthcare sector saw a slight sequential deterioration in earnings delivery against the expectations of Kenanga Research.
The research firm said out of the six companies under its coverage, three came within its forecasts, while three others disappointed.
“Generally, private hospitals under our coverage were hit by less patients seeking treatment during the festive month.
“Viewed as a blip, both IHH Healthcare Bhd and KPJ Healthcare Bhd expect patients to return in subsequent quarters.
“On the other hand, Pharmaniaga Bhd was hit by higher-than expected operating cost,” it stated in a report.
According to the research firm, the weaker-than-expected showing from IHH in the first half of 2023 (1H23) was due to its Singapore and Turkiye operations.
“The Turkiye operations were hit by festive holidays compounded by long weekend holidays as well as the presidential election.
“On the other hand, IHH’s Singapore operation was hit by staff shortage which is easing gradually.”
KPJ’s 1H23 results came in within expectation thanks to higher patient throughput and higher bed occupancy rate (BOR) of 66% (compared to 52% in 1H22) as demand for non-Covid related services rebounded including elective surgeries cases.
The group’s net profit doubled thanks to better overhead absorption on an improved turnover, as well as reduced losses from its new hospitals.
On the sector outlook, Kenanga noted global healthcare expenditures are projected to reach a total of US$10 trillion by 2026, increasing from US$8.4 trillion in 2022, representing a compound annual growth rate of 3.5% during the five-year period.
“In 2023, we expect IHH’s revenue per inpatient growth of 10%-15% (versus. 18% in 2022 due to low base effect in 2021), inpatient throughput growth of 10%-15% and BOR of 60%-73% (versus 56%-70%% in 2022) for its hospitals in Malaysia, Singapore, India and Turkiye.
“We believe the key growth for its inpatient throughput and BOR will be the return of elective surgeries and medical travel, the addition of new beds and the first full-year contribution from the Acibadem Atasehir hospital.”
Similarly, it expects KPJ’s patient throughput to grow 14% (versus 12% in FY22) with BOR of 70%, which will be driven by the recovery in demand for its services, particularly, non-Covid related ones including elective surgeries.
Kenanga Research liked both the stocks for their pricing power being major private healthcare players.
2 weeks ago
this is very weird. goreng all the way without any indication. will it cut chives later?
2 weeks ago
Post a Comment
Featured Posts
Trending Events
MQ Trading Signals
Time
Signal
Duration
Type
2023-09-26 09:14:58
EMA 5
Daily
SELL
Apps
Top Articles
1
2
3
5
6
7
BFM Podcast
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
stainlyho37
Pharmaniaga Bhd's new seven-year concession agreement with the Ministry of Health (MOH) until mid-2030 will maintain the same scope and responsibilities as the previous agreement, which was awarded over two decades ago, for the provision of medical supplies and medicines. (TheEdge)
2 months ago